Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study. ACOU085 is a...
TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study. ACOU085 is a...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.